← Leaderboards
David N Krag
University Of Vermont &St Agric College
$12,737,812
Attributed
$12,737,812
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$12,737,812 · 18
By mechanism
R01$8,176,840 · 3
U01$3,462,079 · 1
R21$900,676 · 2
M01$198,217 · 12
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchMetastasisBreast NeoplasmsImmunocytochemistryBreast SurgeryLigandsNeoplastic CellLymph NodesQuality Of LifeCancer PatientGrantFundingOperative Surgical ProceduresEvaluationPeptide LibraryBone MarrowClinical TrialsDetectionBiopsyExcisionFemaleDiagnostic Neoplasm StagingNeoplasm /Cancer Immunotherapy
Grant awards (46)
Sentinel Node Versus Axillary Dissection in Breast Cancer$685,471
R01 · FY2012 · CA · contact PI
Sentinel Node Versus Axillary Dissection in Breast Cancer$693,246
R01 · FY2011 · CA · contact PI
Sentinel Node Versus Axillary Dissection in Breast Cancer$747,145
R01 · FY2010 · CA · contact PI
Sentinel Node Versus Axillary Dissection in Breast Cancer$751,060
R01 · FY2009 · CA · contact PI
Sentinel Node Versus Axillary Dissection in Breast Cancer$850,024
R01 · FY2007 · CA · contact PI
Targeted Enzymes for Prodrug Therapy$497,767
R01 · FY2007 · CA · contact PI
SERIAL EVALUATION OF SERUM PROTEIN PROFILE FOLLOWING BREAST CANCER TREATMENT$22,895
M01 · FY2007 · RR · contact PI
DETECTION OF RARE DISSEMINATED TUMOR CELLS IN BLOOD AND BONE MARROW$4,579
M01 · FY2007 · RR · contact PI
DETECTION OF MICROMETASTATIC CANCER CELLS IN BLOOD & BONE MARROW - BREAST CANCER$762
M01 · FY2007 · RR · contact PI
IN VIVO SELECTION OF LIGANDS FOR TARGETED THERAPY$762
M01 · FY2007 · RR · contact PI
Sentinel Node Versus Axillary Dissection in Breast Ca.$1,026,959
R01 · FY2006 · CA · contact PI
Targeted Enzymes for Prodrug Therapy$547,334
R01 · FY2006 · CA · contact PI
Targeting Breast Cancer with Small Ligands$280,423
R01 · FY2006 · CA · contact PI
SERIAL EVALUATION OF SERUM PROTEIN PROFILE FOLLOWING BREAST CANCER TREATMENT$50,538
M01 · FY2006 · RR · contact PI
DETECTION OF MICROMETASTATIC CANCER CELLS IN BLOOD/BONE MARROW -BREAST CANCER$8,511
M01 · FY2006 · RR · contact PI
DETECTION OF CANCER CELLS ADDED TO BLOOD SAMPLES TAKEN FROM HEALTHY INDIVIDUALS$7,448
M01 · FY2006 · RR · contact PI
IN VIVO SELECTION OF LIGANDS FOR TARGETED THERAPY$3,192
M01 · FY2006 · RR · contact PI
ADJUVANT ALFA-2B FOR MELANOMA PATIENTS WITH EARLY LYMPH NODE METASTASIS$1,066
M01 · FY2006 · RR · contact PI
DETECTION OF RARE DISSEMINATED TUMOR CELLS IN BLOOD AND BONE MARROW$1,064
M01 · FY2006 · RR · contact PI
Sentinel Node Versus Axillary Dissection in Breast Ca.$489,998
R01 · FY2005 · CA
Targeted Enzymes for Prodrug Therapy$429,215
R01 · FY2005 · CA
Targeting Breast Cancer with Small Ligands$280,505
R01 · FY2005 · CA
SERIAL EVALUATION OF SERUM PROTEIN PROFILE FOLLOWING BREAST CANCER TREATMENT$18,019
M01 · FY2005 · RR
DETECTION OF MICROMETASTATIC CANCER CELLS IN BLOOD/BONE MARROW -BREAST CANCER$8,778
M01 · FY2005 · RR
IN VIVO SELECTION OF LIGANDS FOR TARGETED THERAPY$4,620
M01 · FY2005 · RR
DETECTION OF CANCER CELLS ADDED TO BLOOD SAMPLES TAKEN FROM HEALTHY INDIVIDUALS$4,158
M01 · FY2005 · RR
ADJUVANT ALFA-2B FOR MELANOMA PATIENTS WITH EARLY LYMPH NODE METASTASIS$925
M01 · FY2005 · RR
Targeting Breast Cancer with Small Ligands$295,294
R01 · FY2004 · CA
Detection of Cancer Cells Added to Blood Samples Taken from Healthy Individuals$8,841
M01 · FY2004 · RR
Detection of Micrometastatic Cancer Cells in Blood/Bone Marrow -Breast Cancer$8,841
M01 · FY2004 · RR
In Vivo Selection of Ligands for Targeted Therapy$8,105
M01 · FY2004 · RR
Adjuvant Alfa-2B for Melanoma patients with Early Lymph Node Metastasis$2,210
M01 · FY2004 · RR
Sentinel Node Versus Axillary Dissection--Breast Cancer$772,765
U01 · FY2003 · CA
In Vivo Selection of Ligands for Targeted Therapy$337,088
R21 · FY2003 · CA
Sentinel Node Versus Axillary Dissection--Breast Cancer$204,873
U01 · FY2003 · CA
Sentinel Node Versus Axillary Dissection--Breast Cancer$842,091
U01 · FY2002 · CA
In Vivo Selection of Ligands for Targeted Therapy$337,088
R21 · FY2002 · CA
ADJUVANT INTERFERON ALFA 2B FOR MELANOMA PTS W/ EARLY LYMPH NODE METASTASES$0
M01 · FY2002 · RR
Sentinel Node Versus Axillary Dissection--Breast Cancer$935,110
U01 · FY2001 · CA
TARGETING BREAST CANCER WITH SMALL LIGANDS$304,985
R01 · FY2001 · CA
IDENTIFICATION OF SMALL PEPTIDES WHICH TARGET CANCER CEL$113,250
R21 · FY2001 · CA
SENTINEL NODE IN BREAST CONSERVING THERAPY$707,240
U01 · FY2000 · CA
TARGETING BREAST CANCER WITH SMALL LIGANDS$297,414
R01 · FY2000 · CA
IDENTIFICATION OF SMALL PEPTIDES WHICH TARGET CANCER CEL$113,250
R21 · FY2000 · CA
ADJUVANT INTERFERON ALFA 2B FOR MELANOMA PTS W/ EARLY LYMPH NODE METASTASES$32,903
M01 · FY2000 · RR
ADJUVANT INTERFERON ALFA 2B FOR MELANOMA PTS W/ EARLY LYMPH NODE METASTASES$0
M01 · FY2000 · RR